Cargando…

Infliximab for pediatric patients with Crohn’s disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan

OBJECTIVES: The prevalence of pediatric Crohn’s disease (CD) is increasing in Japan and other countries, and many patients are unresponsive to or do not tolerate current treatment options. This study aimed to investigate the efficacy, safety, and pharmacokinetic profile of infliximab (IFX) in pediat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tajiri, Hitoshi, Motoya, Satoshi, Kinjo, Fukunori, Maemoto, Atsuo, Matsumoto, Takayuki, Sato, Noriko, Yamada, Hiroshi, Nagano, Mieko, Susuta, Yutaka, Ozaki, Kunihiko, Kondo, Kazuoki, Hibi, Toshifumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095542/ https://www.ncbi.nlm.nih.gov/pubmed/30114224 http://dx.doi.org/10.1371/journal.pone.0201956

Ejemplares similares

Correction: Infliximab for pediatric patients with Crohn’s disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan
por: Tajiri, Hitoshi, et al.
Publicado: (2022)

Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan
por: Tajiri, Hitoshi, et al.
Publicado: (2019)

Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study
por: Hibi, Toshifumi, et al.
Publicado: (2016)

Physician–patient communication affects patient satisfaction in treatment decision-making: a structural equation modelling analysis of a web-based survey in patients with ulcerative colitis
por: Matsuoka, Katsuyoshi, et al.
Publicado: (2021)

First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis
por: Kobayashi, Taku, et al.
Publicado: (2015)

Long-Term Clinical Effectiveness of Ustekinumab in Patients With Crohn’s Disease: A Retrospective Cohort Study
por: Ito, Takahiro, et al.
Publicado: (2020)

Infliximab Extends the Duration until the First Surgery in Patients with Crohn's Disease
por: Sakatani, Aki, et al.
Publicado: (2013)

Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial
por: Hisamatsu, Tadakazu, et al.
Publicado: (2018)

A Food Impaction in Crohn’s Ileal Stricture
por: Hokama, Akira, et al.
Publicado: (2010)

Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study
por: Hibi, Toshifumi, et al.
Publicado: (2019)

Efficacy and safety of valbenazine in Japanese patients with tardive dyskinesia: A multicenter, randomized, double‐blind, placebo‐controlled study (J‐KINECT)
por: Horiguchi, Jun, et al.
Publicado: (2022)

Infliximab in the treatment of Crohn’s disease
por: Poggioli, Gilberto, et al.
Publicado: (2007)

Effectiveness of Concomitant Enteral Nutrition Therapy and Infliximab for Maintenance Treatment of Crohn’s Disease in Adults
por: Hirai, Fumihito, et al.
Publicado: (2012)

Infliximab- and Immunosuppressant-Resistant Crohn's Disease Successfully Treated with Adsorptive Granulocyte Apheresis Combined with Prednisolone
por: Itagaki, Munenori, et al.
Publicado: (2012)

Infliximab to treat Crohn’s disease: an update
por: Cottone, M, et al.
Publicado: (2011)

Long-term effectiveness and safety of infliximab-biosimilar: A multicenter Phoenix retrospective cohort study
por: Kazama, Tomoe, et al.
Publicado: (2023)

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
por: Vande Casteele, Niels, et al.
Publicado: (2015)

Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn's Disease
por: Gomes, Luis Eduardo Miani, et al.
Publicado: (2019)

Profile of infliximab in the treatment of pediatric Crohn’s disease
por: Kierkus, Jaroslaw, et al.
Publicado: (2015)

Metastatic Crohn’s disease despite infliximab therapy
por: Campos, Sara, et al.
Publicado: (2017)

Myelolipoma After Infliximab Treatment for Crohn's Disease
por: Cesa, Kevin, et al.
Publicado: (2022)

Infliximab for medical induction of remission in Crohn's disease
por: Gordon, Morris, et al.
Publicado: (2023)

Monitoring of leucine‐rich alpha‐2‐glycoprotein and assessment by small bowel capsule endoscopy are prognostic for Crohn's disease patients
por: Ito, Takahiro, et al.
Publicado: (2023)

Capsule endoscopy findings for the diagnosis of Crohn’s disease: a nationwide case–control study
por: Esaki, Motohiro, et al.
Publicado: (2018)

Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease
por: Oh, Eun Hye, et al.
Publicado: (2017)

Infliximab therapy in pediatric Crohn’s disease: a review
por: Parashette, Kalyan Ray, et al.
Publicado: (2010)

Maintenance treatment with infliximab for the management of Crohn’s disease in adults
por: Caviglia, Renato, et al.
Publicado: (2009)

Infliximab-induced intertriginous psoriasis in patient with Crohn's disease
por: Mola, Federica, et al.
Publicado: (2011)

Refractory Duodenal Crohn's Disease Successfully Treated with Infliximab
por: Kim, You Lim, et al.
Publicado: (2014)

Infliximab in the Treatment of Crohn Disease and Type 1 Diabetes
por: Timper, Katharina, et al.
Publicado: (2013)

Efficacy of Infliximab for the Treatment of Oral Manifestation of Crohn’s Disease
por: Aginbay, Aibar, et al.
Publicado: (2022)

Diagnosis and Clinical Features of Perianal Lesions in Newly Diagnosed Crohn’s Disease: Subgroup Analysis from Inception Cohort Registry Study of Patients with Crohn’s Disease (iCREST-CD)
por: Yamamoto, Takayuki, et al.
Publicado: (2023)

Evidence-based clinical practice guidelines for Crohn’s disease, integrated with formal consensus of experts in Japan
por: Ueno, Fumiaki, et al.
Publicado: (2012)

Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn’s Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab
por: Sorrentino, Dario, et al.
Publicado: (2015)

Infliximab-Induced Aseptic Meningitis in a Patient with Crohn’s Disease
por: Junga, Zachary, et al.
Publicado: (2018)

Early intestinal obstruction after infliximab therapy in Crohn’s disease
por: Chiba, Mitsuro, et al.
Publicado: (2019)

Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
por: Im, Jong Pil
Publicado: (2017)

Optimized timing of using infliximab in perianal fistulizing Crohn's disease
por: Sun, Xue-Liang, et al.
Publicado: (2020)

Gummatous cutaneous tuberculosis associated with the use of infliximab for Crohn's disease()()
por: Garcia, Lucas Campos, et al.
Publicado: (2021)

Cortical Vein Thrombosis after Infliximab Treatment for Crohn’s Disease
por: Razmeh, Saeed, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a80p6on6iv8u24nt88istu5hoj